NEWS

Mindset and InterVivo Solutions Announce Availability of First Preclinical Psychedelic Benchmark Data from COPE Program

June 14, 2021

TORONTO, June 14, 2021 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, and InterVivo Solutions (“InterVivo”), today announced the availability

Read More

Mindset Selects its Lead Clinical Candidate, MSP-1014, a Next Generation Psychedelic Medicine

June 3, 2021

TORONTO, June 03, 2021 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that it has selected its lead clinical candidate, MSP-1

Read More

Mindset Announces Participation at Upcoming Events in June 2021

June 1, 2021

Toronto, Ontario--(Newsfile Corp. - June 1, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs, today announced that James Lanthier, CEO of Mindset, will participate

Read More

Mindset Pharma Invited to Present at Canaccord Genuity 41st Annual Growth Conference

May 5, 2021

Toronto, Ontario--(Newsfile Corp. - May 5, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that it has been invited to present at the Canaccord Genuity 41st Annual Growth Conference being held August 10-12, 2021.

Read More

Mindset Pharma Announces Positive Preclinical Results of Its Proprietary Next Generation DMT & 5-MeO-DMT Compounds

April 29, 2021

Toronto, Ontario--(Newsfile Corp. - April 29, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that certain of Mindset's Family 4 compounds, a group of patent-pending novel chemical entities that are inspired by DMT & 5-MeO-DMT, are exhibiting positive in vitro screening characteristics.

Read More

Mindset Pharma Engages KCSA Strategic Communications to Provide Investor Relations Services

April 28, 2021

Toronto, Ontario--(Newsfile Corp. - April 28, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") announces that it has entered into an agreement with KCSA Strategic Communications ("KCSA") to provide investor relations services effective as of May 15, 2021. KCSA is a fully integrated communications consultancy with a creative and strategic approach to pu

Read More

Mindset Pharma Invited to Present at H.C. Wainwright "Psychedelics in Psychiatry and Beyond" Virtual Conference

April 26, 2021

Toronto, Ontario--(Newsfile Corp. - April 26, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that it has been invited to present at the H.C. Wainwright "Psychedelics In Psychiatry and Beyond" Virtual Conference being held on June 17, 2021.

Read More

Mindset Pharma Announces Strong Confirmation of In Vivo Proof-of-Concept Across Its Entire New Drug Program Portfolio

April 20, 2021

Toronto, Ontario--(Newsfile Corp. - April 20, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce, that based on data derived from Mindset's in vivo testing program (i.e. testing in animal subjects) carried out by InterVivo Solutions Inc., the Company has confirmed that the majority of its patent pending compounds across four famili

Read More

Mindset Pharma Announces Exercise of Over-Allotment Option for Additional Gross Proceeds of $1.052 Million

April 19, 2021

Toronto, Ontario--(Newsfile Corp. - April 19, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that in connection with its previously announced "bought deal" public offering (the "Offering") underwritten by Canaccord Genuity Corp. (the "Lead Underwriter"), as lead underwriter and sole bookrunner, along with Stifel Nicolaus Canada

Read More

Mindset Pharma Announces Closing of $7.5 Million Bought Deal Public Offering

April 15, 2021

Toronto, Ontario--(Newsfile Corp. - April 15, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that it has completed the previously announced "bought deal" public offering through the issuance of an aggregate of 10,000,000 units (each, a "Unit") of the Company at a price of $0.75 per Unit (the "Issue Price") for aggregate gross p

Read More

Mindset Pharma Expands Scientific Team: Dr. Malik Slassi Appointed Senior VP Innovation and Ian Dean Appointed Director Preclinical Development

March 30, 2021

Toronto, Ontario--(Newsfile Corp. - March 30, 2021) - Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin and N,N-Dimethyltryptamine (DMT) inspired medicines and related technologies, is pleased to announce that it has expanded its scientific leadership team with the appoin

Read More

Mindset Pharma and InterVivo Solutions to Jointly Develop Advanced Cooperative Psychedelics Evaluation Platform ("Cope"); Cope Expected to Be World's First in Vivo Psychedelic Benchmark Data Set

March 23, 2021

Toronto, Ontario--(Newsfile Corp. - March 23, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a biotechnology company focused on developing next generation psychedelic medicines and related technologies, is pleased to announce that it has entered a co-development agreement with InterVivo Solutions Inc. ("InterVivo" or "IVS"), to co-develop a new tran

Read More

Mindset Pharma Announces $5 Million Bought Deal Financing

March 22, 2021

TORONTO, March 22, 2021 /CNW/ - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp., as sole bookrunner and lead underwriter (the "Lead Underwriter") pursuant to which the Lead Underwriter has agreed, on behalf of a syndicate of underwriters (together with the Lead Underwrit

Read More

Mindset Pharma Announces Upsize of Bought Deal to $7.5 Million

March 22, 2021

TORONTO, March 22, 2021 /CNW/ - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that in connection with its previously announced bought deal public offering, the Company and Canaccord Genuity Corp., as sole bookrunner and lead underwriter (the "Lead Underwriter"), on behalf of a syndicate of underwriters (together with the Lead Underwri

Read More

Mindset Pharma Announces DTC Eligibility for OTCQB Venture Listing

March 17, 2021

Toronto, Ontario--(Newsfile Corp. - March 17, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that it has received confirmation of eligibility from The Depository Trust Company ("DTC") for elect

Read More

Mindset Pharma Files a Sixth U.S. Provisional Patent, Further Expanding Its Psychedelic Drug Candidates Pipeline With Novel DMT & 5-MeO-DMT Analogs

March 15, 2021

Toronto, Ontario--(Newsfile Corp. - March 15, 2021) - Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) ("Mindset" or the "Company") is pleased to announce that it has filed a sixth provisional patent application with the United States Patent and Trademark Office. This most recent patent application covers a comprehensive range of novel N,N-Dimethyltryptamine ("DMT") and 5-methoxy-N,N-dimethyltryptamine

Read More

Mindset Pharma Appoints Leading Molecular Pharmacologist & Formulation Expert Dr. Joseph Gabriele to Scientific Advisory Board

March 8, 2021

Toronto, Ontario--(Newsfile Corp. - March 8, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company") is pleased to announce that it has appointed Dr. Joseph Gabriele, a molecular pharmacologist specializing in signal transduction within the central nervous system, to its scientific advisory board ("Scientific Advisory Board"). Dr. Gabriele specializes in molecular pharmacol

Read More

Mindset Pharma Reaches Agreement to Manufacture Large Quantity of Pharmaceutical Grade Psilocybin Using Patent-Pending Synthesis Process

February 22, 2021

Toronto, Ontario--(Newsfile Corp. - February 22, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that it has engaged a leading international contract development and manufacturing organization ("CDMO") to synt

Read More

Mindset Pharma Added to North American Psychedelics Index

February 19, 2021

Toronto, Ontario--(Newsfile Corp. - February 19, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that effective today, it has been added to the North American Psychedelics Index which is provided by German-bas

Read More

Mindset Announces Milestone in New Drug Program with Successful Proof-of-Concept Animal Studies of Its Patent-Pending Psilocybin-Inspired Drug Candidates

February 10, 2021

Toronto, Ontario--(Newsfile Corp. - February 10, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that several of its proprietary, novel and diverse psychedelic compounds are demonstrating strong potency and e

Read More

Mindset Files Multiple Final Patent Applications on Its Novel Psilocybin-Inspired Compounds

February 5, 2021

Toronto, Ontario--(Newsfile Corp. - February 5, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a leading drug discovery and development company focused on the development novel next generation psilocybin-inspired medicines and related technologies, is pleased to announce that the Company has filed 3 final patent applications with the U.S. Patent and Trademark Offi

Read More

Mindset Selects Compounds from Its Third Psilocybin-Inspired Drug Family to Move into in vivo PoC Studies

February 1, 2021

Toronto, Ontario--(Newsfile Corp. - February 1, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing novel next generation psilocybin-inspired medicines and related technologies, is pleased to announce it has selected a subset of representative compounds belonging to its proprietary third family of patent-pe

Read More

Mindset Pharma Announces Listing on the Frankfurt Stock Exchange

January 27, 2021

Toronto, Ontario--(Newsfile Corp. - January 27, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that its common shares have been accepted for listing on the Frankfurt Stock Exchange (the "FSE") and commenced t

Read More

Mindset Pharma to Present at Inaugural KCSA Psychedelic Investor Conference

January 20, 2021

Toronto, Ontario--(Newsfile Corp. - January 20, 2021) - Mindset Pharma Inc. (CSE:MSET) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce it has been invited to present at the inaugural KCSA Psychedelic Investor Conference being held on Tuesday, January 26, 2021

Read More

Mindset Pharma Invited to Present at Upcoming Canaccord Genuity Mental Health Conference

January 14, 2021

Toronto, Ontario--(Newsfile Corp. - January 14, 2021) - Mindset Pharma Inc. (CSE: MSET) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psychedelic medicines and related technologies, is pleased to announce it has been invited to present at the Canaccord Genuity conference "New Paradigms & Treatment Approaches in Mental Health", being he

Read More